CoagulationAnalyzers Market By Product (Instruments [Automated Analyzers,
Semi-Automated Analyzers, Manual Analyzers], Reagents and Consumables), By Test
Type (Fibrinogen Testing, Activated Clotting Time Testing (Act), D-Dimer
Testing, Platelet Function Testing, Others), By Technology (Optical Technology,
Mechanical Technology, Electrochemical Technology, Others), By End-User
(Hospitals, Diagnostic Centers, and Others), and By Geography is anticipated to
grow at a significant CAGR forecast till 2026 owing to rising prevalence of
thromboembolytic disease, bleeding disorders and increase in the availability
of more advanced products.
Global Coagulation Analyzers Market was valued at USD 4.19 billion in 2020, growing
at a CAGR of 5.44% during
the forecast period from 2021 to 2026, to reach USD 5.74 billion by 2026. The demand for Coagulation
Analyzers is predominantly associated with the rising prevalence of
thromboembolytic disease and bleeding disorders such as impaired liver
function, hemophilia, and von Willebrand disease. Moreover, the increase in the
availability of more advanced analyzers, growing awareness about these diseases
and their management, rising geriatric population base are some of the factors
likely to boost the Global Coagulation Analyzers Market during the forecast
period.
Get detailed information @ Coagulation Analyzers Market Insights
The Coagulation Analyzers Market has significantly increased
owing to the fact that coagulation analysis allows for faster and efficient
assessment of blood platelet levels, as well as determining the velocity of
different concentrations.
According to the Centers for Disease Control and Prevention
2020, people with hemophilia have unique risk factors that may lead them to
heart disease as their life expectancy increases, such as infusion of factor
concentrates and infection with HIV. Owing to the growing burden of
lifestyle-associated and chronic blood disorders across the globe, the
Coagulation Analyzers market has been rising significantly. Similarly, as per
Haemophilia Foundation Australia 2021, Haemophilia occurs in 1 in 6,000-10,000 males
internationally. According to the same statistics, in Australia,
there are more than 3,000 people
diagnosed with varying degrees of severity of Haemophilia.
Another factor responsible for the growth of the Coagulation
Analyzers market is the prevalence of von Willebrand disease (VWD). As per the
Centers for Disease Control and Prevention 2021, VWD is the most common
bleeding disorder, found in up to 1% of
the US population. This means that 3.2
million (or about 1 in
every 100) people in the United States have the disease.
Chronic blood disorders have a significant impact on the
health and quality of life of patients and their families. They can cause pain,
loss of normal functioning, depression, and anxiety, financial burden,
long-term hospitalization, and even death. Therefore, to properly treat and
manage chronic blood disorders like Haemophilia and VWD, Coagulation Analyzers
devices are required. These devices help to detect clotting deficiencies,
measure coagulation pathways speed, thrombolin levels and are also used to
monitor the effects of drugs on whole blood. Since their use is quite extensive
and offers wide applications in blood disorders, thus the demand for these
devices will grow, which in turn is expected to drive the Global Coagulation
Analyzers market.
Comments
Post a Comment